INTRODUCTION
Myocardial hypertrophy allows the heart to maintain or increase its haemodynamic output in response to a requirement for increased pressure-volume work (e.g. during hypertension), or a requirement to counteract necrosis\apoptosis of the cardiac myocytes induced, most commonly, by myocardial infarction. In i o, the primary inducers of hypertrophy are not clear, but the response is likely to be mediated, at least in part, by autocrine\ paracrine effects of locally released agents such as the vasoactive peptide endothelin-1 (ET-1) or noradrenaline (acting through the α " -adrenoceptor). In primary cultures of neonatal rat ventricular myocytes, both ET-1 and the synthetic α " -adrenergic agonist phenylephrine (PE) induce many of the alterations seen in hypertrophy in i o. These include numerous changes in gene expression, including a rapid and transient up-regulation of immediate early genes such as c-jun [1] , a later recapitulation of a ' foetal ' pattern of gene expression and up-regulation of genes encoding constitutively expressed contractile proteins [1, 2] . The transient expression of immediate early genes is thought to play a role in the ensuing changes in gene expression.
Many lines of evidence have implicated the mitogen-activated protein kinases (MAPKs) in the hypertrophic response [3, 4] . Three MAPK subfamilies have been well characterized : the extracellular signal-regulated kinases 1 and 2 (ERK1\2), the cJun N-terminal kinases (JNKs) and the p38-MAPKs [5] . In cardiac myocytes, ERK1\2 are potently activated by G q -proteincoupled receptor agonists, including ET-1 and PE, through protein kinase C (PKC) [3] . PMA, by activating PKC directly, strongly activates ERK1\2. ET-1 and PE also activate JNKs and p38-MAPKs, but these kinases are more potently stimulated by cellular stresses such as hyperosmotic shock or oxidative stress [4] . We and others have suggested that ERK1\2 are important in the hypertrophic adaptation of the heart [3, 6] . Others have provided evidence that JNKs or p38-MAPKs participate in this response [4] . Recent experiments in transgenic mice indicate that activation of ERK1\2 produces compensated hypertrophy [7] .
Transcriptional up-regulation of immediate early genes results from the activation of pre-existing transcription factors which bind to specific regulatory elements in the promoter regions of these genes. Many immediate early genes themselves encode transcription factors which can subsequently activate other genes.
The rat c-jun promoter region contains several regulatory elements including two activator protein 1 (AP-1)\cAMP-response element (CRE)-like sites [8] . The AP-1\CRE-like sites are the dominant elements in the up-regulation of c-jun expression under some circumstances [9, 10] , and bind heterodimers of c-Jun and activating transcription factor 2 (ATF2) [11, 12] . Through this mechanism, it may be possible for c-Jun to up-regulate its own expression. The transactivating activities of c-Jun and ATF2 are increased by the phosphorylation of specific Ser\Thr residues in their N-terminal transactivation domains [13] [14] [15] [16] . c-Jun was first shown to be phosphorylated in its transactivation domain (Ser-63 and Ser-73) by ERKs and p54-JNK [17] . Subsequent studies indicated that JNKs have a higher affinity for c-Jun as a substrate and that these MAPKs, rather than ERKs, are responsible for c-Jun phosphorylation [13, 18, 19] .
In cardiac myocytes, c-Jun and ATF2 are both phosphorylated in their transactivation domains in response to hyperosmotic shock, but there is no de no o synthesis of c-Jun protein [20] . This suggests that activation of JNKs and phosphorylation of c-Jun are not the sole factors required for up-regulation of c-Jun protein [20] . However, since hyperosmotic shock inhibits protein synthesis by 95 % (F. Pham and A. Clerk, unpublished work), there remained the possibility that c-Jun phosphorylation could still promote an increase in c-jun transcription. Our previous studies implicated ERK1\2 in the up-regulation of c-Jun protein in cardiac myocytes exposed to interleukin-1β (IL-1β) [21] . However, in NIH-3T3 cells overexpressing the muscarinic m1 acetylcholine receptor, stimulation of c-jun expression is mediated through JNKs, p38-MAPKs (α and γ isoforms) and an additional member of the ERK family, ERK5 [22] . Whereas JNKs and p38-MAPKα act primarily on the proximal AP-1\CRE-like site [22] , ERK5 activates the myocyte-specific enhancer-binding factor 2 (MEF2) transcription factor(s) [23] that, in the c-jun promoter, acts at a site immediately 3h to the proximal AP-1\CRE-like site [8, [22] [23] [24] . Here we have examined the regulation of c-jun expression at the mRNA and protein level in cardiac myocytes exposed to hypertrophic stimuli or PMA. Our studies suggest that ERK1\2 are the principal kinases which promote upregulation of c-jun mRNA, but ERK1\2 alone are insufficient for efficient up-regulation of c-Jun protein. An additional input is required from JNKs, probably to stabilize the protein.
EXPERIMENTAL Preparation of neonatal rat cardiac myocytes
Myocytes were dissociated from the ventricles of neonatal Sprague-Dawley rat hearts as described previously [25] , and plated in 10 % (v\v) horse serum and 5 % (v\v) foetal calf serum for 18 h, at a density of 1.4i10$ cells\mm#. Serum was withdrawn for 24 h prior to experimentation. Myocytes were exposed to agonists (PMA, 1 µM ; ET-1, 0.1 µM ; PE, 100 µM) for the times indicated. Where appropriate, myocytes were pretreated with inhibitors (10 min) and the cells incubated with agonist in the presence of the inhibitor. U0126, PD98059, GF109203X and SP600125 were from Calbiochem and stock solutions were prepared in DMSO at 10 mM (U0126, GF109203X, SP600125) or 25 mM (PD98059). LY294002 was from Alexis Biochemicals and a 50 mM stock solution was prepared in DMSO. Cycloheximide was from Sigma and dissolved in water. Agonists and inhibitors were added directly to the tissue culture medium.
Ratiometric reverse transcriptase PCR (RRT-PCR)
Total RNA was extracted using RNAzol B (AMS Biotechnology Europe) according to the manufacturer's instructions, and the quantity and purity were assessed from the A #'! and the A #'! \A #)! (values of 1.4-1.9 were considered satisfactory). RRT-PCR was performed as described previously [26] . Primers were designed (forward primer, 5h-ATGACTGCAAAGATGGAAACG-3h ; reverse primer, 5h-TATTCTGGCTATGCAGTTCAG-3h) from the published rat c-jun sequence (EMBL accession number X17215 [8] 
Quantitative RT-PCR
Expression levels of rat c-jun mRNA were detected by PCR amplification and quantified by 5h nuclease assay [27] using fluorescently labelled TaqMan probes analysed using real-time quantitative PCR [28] . Hexamer-primed cDNA synthesis was performed on 200 ng of total RNA in a volume of 20 µl using the Applied Biosystems reverse transcriptase kit (Applied Biosystems catalogue no. N8080234) and then stored at 20 mC. The sequences of primers and probe for c-jun cDNA were designed using the Primer Express Software (Applied Biosystems) from the published rat c-jun sequence. These were : forward primer, 5h-CGGAGAGGAAGCGCATGA-3h (melting point, T m l 52.4 mC) ; reverse primer, 5h-GATCCGCTCCAGCTTCCTT-3h (T m l 53.1 mC) ; and probe, 5h-CATCGCTGCCTCCAAGTGC-CG-3h (T m l 69 mC). The predicted c-jun amplicon size was 68 bp. Internal control 18 S rRNA primers and the TaqMan probe were provided as part of a pre-optimized kit (Applied Biosystems catalogue no. 4310893E). PCR amplifications were performed in a 25 µl volume containing 2.5 µl of cDNA template in 2iPCR Master Mix (Applied Biosystems) at 50 mC for 2 min, 95 mC for 10 min followed by 40 cycles of 95 mC for 15 s and 60 mC for 1 min. Reactions were performed and products detected using an ABI-Prism 7700 sequence detector. Each sample was analysed in duplicate. There was no detectable interference by genomic DNA as shown by omission of the reverse transcriptase step. Results were analysed using Sequence Detection Software (Applied Biosystems) and the level of expression of c-Jun mRNA normalized to 18 S rRNA as outlined in User Bulletin F 2 provided by Applied Biosystems. Amplification of 18 S rRNA and c-jun mRNA was co-linear (results not shown).
Immunoblot analysis
Myocytes were unstimulated or pretreated with inhibitors (10 min), and then exposed to agonists in the presence or absence of inhibitors. For analysis of ERK activation total extracts were prepared, and for analysis of c-Jun phosphorylation and upregulation nuclear extracts were prepared, and phosphorylated and total proteins were analysed by immunoblotting as described previously [20] . Proteins were detected using primary antibodies to phospho-ERKs, total ERKs, phospho-c-Jun or total c-Jun (1\1000 ; New England Biolabs), horseradish peroxidaseconjugated secondary antibodies and visualized by enhanced chemiluminescence. For phosphorylated c-Jun, blots were probed with a combination of antibodies selective for phosphorylation on Ser-63 and Ser-73. Scanning densitometry was used for semi-quantitative analysis of the data. Results are expressed as meanspS.E.M.
RESULTS

Hypertrophic stimuli, but not hyperosmotic shock, up-regulate c-jun transcription in cardiac myocytes
Transcription of c-jun is thought to be regulated by c-Jun\ATF2 heterodimers acting at AP-1\CRE-like sites in the c-jun promoter. Phosphorylation of c-Jun by JNKs may regulate c-jun expression. We directly compared the effects of hypertrophic stimuli and hyperosmotic shock (which may increase c-jun expression in the absence of any increase in protein) on c-jun transcription using semi-quantitative RRT-PCR and by quantitative real-time RT-PCR. c-jun mRNA was detectable under basal conditions ( Figure  1 ). PMA (1 µM) promoted a significant increase (5.5p1.2-fold, n l 4) in c-jun mRNA ( Figure 1A ) even though it does not significantly activate JNKs or p38-MAPKs [29, 30] . Increased expression of c-jun mRNA was detected within 15 min and was maximal at 30-45 min. ET-1 (0.1 µM) increased c-jun mRNA expression to a similar degree as PMA (5.8p1.0-fold, n l 5). This was also maximal at 30 min, but decreased from 45 min ( Figure 1B) . The stimulation of c-jun mRNA expression by 100 µM PE (3.7p0.7-fold, n l 3 ; Figure 1C ) was less than that induced by either PMA or ET-1, although the time course of stimulation was similar to that for ET-1 ( Figure 1B) . In contrast to hypertrophic stimuli, hyperosmotic shock (0.5 M sorbitol) did not promote any significant increase in c-jun expression ( Figure  1D ), despite potent activation of JNKs [29] and phosphorylation of c-Jun [20] . These data indicate that JNKs are not the principal kinases involved in the up-regulation of c-jun transcription in cardiac myocytes.
To investigate further which kinases may regulate c-jun expression, we examined the effects of a range of protein kinase inhibitors on the stimulation of c-jun expression by PMA and ET-1. Neither the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 (50 µM) nor 10 µM SB203580 (which inhibits p38-MAPKs and p46-JNK1 isoforms in cardiac myocytes [30, 31] ) had any effect on the stimulation of c-jun expression by PMA (Figure 2A ) or ET-1 ( Figure 2B ). The recently described JNK inhibitor, SP600125 (10 µM) [32] , also had no effect on the stimulation of c-jun expression by ET-1 ( Figure 3 ). However, upregulation of c-jun mRNA by PMA or ET-1 was inhibited by the 
Figure 4 U0126 or PD98059, but not LY294002, SB203580 or SP600125, inhibit activation of ERKs by ET-1
Myocytes were unstimulated (Control), exposed to 10 µM U0126, 25 µM PD98059, 50 µM LY294002, 10 µM SB203580 or 10 µM SP600125, or exposed to ET-1 (100 nM, 5 min) in the absence or presence of inhibitors. Activation of ERKs was detected by immunoblotting with antibodies selective for the phosphorylated forms (upper panels). Samples were also immunoblotted for total ERKs (lower panels). U0126 or PD98059, but not LY294002, SB203580 or SP600125, inhibited the phosphorylation of ERKs induced by ET-1 and the shift to a reducedmobility (i.e. more phosphorylated) form seen on immunoblots of total ERKs. Up-regulation of c-Jun in cardiac myocytes 
Figure 6 Efficient up-regulation of c-Jun protein by ET-1 requires both the ERK1/2 cascade and JNKs
(A-C) Myocytes were unstimulated (Control) or exposed to 0.1 µM ET-1 for 60 min in the absence or presence of 10 µM Ro318220, 10 µM GF109203X, 25 µM PD98059, 50 µM LY294002 or SB203580 (1 or 10 µM). (D, E) Myocytes were unstimulated (Control) or exposed to 0.1 µM ET-1 for 30 or 60 min in the absence or presence of 10 µM SP600125 (SP). Nuclear extracts were immunoblotted with antibodies to total c-Jun (A, B, E, upper panels) or antibodies selective for phosphorylated c-Jun(Ser-63/73) (C, D, upper panels). The blots were analysed by scanning densitometry and the combined data are shown in the lower panels as meanspS.E.M. for three (PD98059 or SB203580), four (LY294002 or SP600125) or five (Ro318220 or GF109203X) separate preparations of myocytes. *P 0.005, †P 0.05 relative to ET-1 alone (unpaired two-tailed Student's t test). Sorb, sorbitol.
PKC-selective inhibitor GF109203X (10 µM), or inhibitors of the ERK cascade [PD98059 (25 µM) or U0126 (10 µM)] ( Figure  2 ). We have previously demonstrated that GF109203X inhibits the activation of ERKs by ET-1 [33] , and confirmed that U0126 and PD98059, but not LY294002, SB203580 or SP600125, did indeed inhibit ET-1 stimulation of ERK activity (Figure 4 ). Experiments also confirmed that SB203580 inhibited p38-MAPK activation of MAPK-activated protein kinase 2 in myocytes exposed to ET-1, and that LY294002 inhibited PI3K-dependent activation of protein kinase B by insulin (results not shown and [33, 34] ). These data indicate that activation of PKC and the ERK cascade, but not the JNK or p38-MAPK pathways, is a key signalling pathway leading to the up-regulation of c-jun mRNA by PMA or ET-1.
ET-1 or PE, but not PMA, can up-regulate c-Jun protein
Although c-Jun protein is detectable under basal conditions, ET-1 or PE promoted an $ 4-fold increase in expression ( Figures 5A and 5B). For both agonists, maximal c-Jun expression was observed at 45-60 min. PMA promoted a small increase in c-Jun protein which was maximal at 15-30 min ( Figure 5C ). Direct comparison of the different agonists indicated a rank order of potency of ET-1 $ PE IL-1β $ tumour necrosis factor α $ PMA with respect to c-Jun protein up-regulation ( Figure  5D ). Hyperosmotic shock did not increase c-Jun protein, consistent with the absence of any increase in c-jun mRNA ( Figure  1D ), and our previous results [20] . Although PMA and ET-1 induced a similar up-regulation of c-jun mRNA (5.5p1.5-fold
Figure 7 Activation of the JNK cascade by ET-1 increases c-Jun stability
Myocytes were unstimulated or exposed to 0.1 µM ET-1 for 1 h. Cells were then either not treated further, or 10 µM SP600125 (SP) and/or 20 µM cycloheximide (CHX) was added to the tissue culture medium. Cells were harvested at the indicated times following treatment with ET-1 for 1 h. Nuclear extracts were immunoblotted with antibodies to total c-Jun (upper panels). The blots were analysed by scanning densitometry and the combined data are shown in the lower panels as meanspS.E.M. for three separate preparations of myocytes.
and 5.8p1.0-fold), which was greater than that induced by PE (3.7p0.7-fold ; Figures 1A-1C) , a direct comparison showed that the increase in c-Jun protein induced by PMA was significantly less than that induced by ET-1 (P 0.05 ; Figure 5D ), whereas the increase induced by PE was similar. These data indicate that, in addition to transcriptional regulation, c-Jun expression is also regulated at the level of translation or protein stability.
Since the phosphorylation of Ser-63 and Ser-73 in the c-Jun transactivation domain by JNKs is particularly important in its activation [18, 19] , we examined the effects of ET-1, PE and PMA on c-Jun phosphorylation by immunoblotting with antibodies selective for phosphorylated c-Jun(Ser-63) and c-Jun(Ser-73). To obtain a reliable signal, both antibodies were combined on a single blot. ET-1 or PE induced substantial increases in c-Jun phosphorylation ( Figures 5E and 5F ). Increased c-Jun phosphorylation was clearly detected within 15-30 min and was maximal at 45-60 min. PMA also increased c-Jun phosphorylation from 5 min ( Figure 5G ), but to a lesser extent than either ET-1 or PE ( Figure 5D , upper panel), and maximal phosphorylation was detected at $15 min ( Figure 5G ). For all three agonists, the level of phosphorylated c-Jun correlated closely with the changes in total c-Jun (Figures 5A-5C ).
As with c-jun mRNA, PD98059 (25 µM) or PKC inhibitors [Ro318220 (10 µM) or GF109203X (10 µM)], but not LY294002 (50 µM), suppressed the stimulation of c-Jun protein phosphorylation and up-regulation by ET-1 ( Figures 6A-6C) , clearly implicating PKC and ERK1\2 in these responses. The results with SB203580 were less clear. At a concentration which inhibits p38-MAPKs in cardiac myocytes (1 µM) [31] , SB203580 had no effect on c-Jun levels, either in unstimulated myocytes or in myocytes exposed to ET-1. Exposure of myocytes to 10 µM SB203580 increased the basal level of expression of c-Jun protein and it was not possible to ascertain from this experiment whether p46-JNK1 is involved in c-Jun phosphorylation or up-regulation. However, SP600125 (10 µM) significantly inhibited the phosphorylation of c-Jun induced by ET-1 at 30 or 60 min, or that induced by 0.5 M sorbitol ( Figure 6D ), consistent with a role for JNKs in this response. SP600125 had no significant effect on the basal levels of c-Jun protein in myocytes exposed to ET-1 for 30 min, but significantly attenuated the increase in c-Jun induced by ET-1 over 60 min ( Figure 6E ). These data suggest that JNKs influence the accumulation of c-Jun, even though there is no effect of this cascade on c-jun transcription. We therefore examined the effect of SP600125 on c-Jun stability. Myocytes were exposed to ET-1 for 1 h, the time at which maximal c-Jun protein is detected ( Figure 5A ). Cycloheximide (20 µM) and\or SP600125 (10 µM) were then added to inhibit protein synthesis and\or JNKs, and the levels of total c-Jun protein were examined over the subsequent 3 h (Figure 7 ). In the absence of either cycloheximide or SP600125, the amount of cJun following 4 h stimulation with ET-1 was 24.2p3.5 % (n l 3) relative to the amount at 1 h. SP600125 alone increased the rate at which c-Jun declined, such that 2 h following addition of the inhibitor c-Jun levels were comparable with those of unstimulated myocytes (1.7p8.3 %, relative to 1 h ET-1 ; n l 3) and by 3 h levels of c-Jun were less than in the unstimulated controls. Cycloheximide, which potently activates JNKs [35] , increased the stability of c-Jun and, over the 3 h period studied, there was no decline in c-Jun protein (114.7p8.3 %, relative to 1 h ET-1 ; n l 3). However, SP600125 significantly increased the rate of degradation of c-Jun protein in the presence of cycloheximide from 1 h and, by 3 h, levels of c-Jun were not significantly different from those in myocytes exposed to ET-1 alone (36.4p15.0 %, relative to 1 h ET-1, n l 3). Although the effect of SP600125 alone could indicate a role for JNKs in increasing c-Jun protein expression and\or reducing c-Jun degradation, the effect of this inhibitor in the presence of cycloheximide strongly suggests that the prime effect of JNKs is to increase cJun stability.
DISCUSSION
The c-jun promoter contains at least eight regulatory elements [8] , but early studies indicated that the key sites important for the up-regulation of c-jun by UV stress are the two AP-1\CRE-like sites [9, 10] , and that the transcription factors acting at these sites are c-Jun\ATF2 heterodimers [11, 12] . This role of c-Jun, acting within the c-jun promoter, suggested a positive feedback system, and it is generally accepted that phosphorylation of c-Jun by JNKs can lead to c-jun expression. However, phorbol esters do not significantly activate JNKs, but increase c-jun mRNA expression in a number of cell types [36, 37] , and this is clearly the case in cardiac myocytes ( [38] and Figure 1A ). In contrast, hyperosmotic shock, which promotes c-Jun phosphorylation [20] , had no effect on c-jun expression ( Figure 1D ), indicating that phosphorylation of c-Jun(Ser-63\73) by JNKs is not the sole driving force for up-regulation of c-jun mRNA.
ET-1 and PE, like PMA, promoted up-regulation of c-jun mRNA ( Figures 1B and 1C) , and the time courses were comparable to that of PMA ( Figure 1A ). The degree of up-regulation by the three agonists correlated with their relative activation of ERK1\2 [6, 39] , and up-regulation of c-jun mRNA by PMA or ET-1 was attenuated by inhibitors of PKC or the ERK cascade (Figure 2 ). PD98059 and U0126, albeit at higher concentrations, also inhibit the ERK5 cascade [40, 41] , a pathway which is implicated in c-jun up-regulation through MEF2 transcription factors [22] [23] [24] , but our preliminary data indicate that in cardiac myocytes, ERK5 is activated by hyperosmotic shock (P. H. Sugden, unpublished work), which does not induce c-jun expression ( Figure 1D ). ERK5, therefore, is clearly not sufficient to promote up-regulation of c-jun mRNA. ET-1 also activates ERK5 (to a lesser extent than hyperosmotic shock ; P. H. Sugden, unpublished work), so it is possible that ERK5 could contribute to the up-regulation of c-jun mRNA by this agonist. However, given that PMA (which activates ERK1\2) up-regulates c-jun mRNA whereas 0.5 M sorbitol (which activates ERK5) does not, the balance of evidence lies in favour of ERK1\2 promoting c-jun expression rather than ERK5. Studies in other cells have implicated p38-MAPKs in the regulation of c-jun transcription [22] . In cardiac myocytes, SB203580 (a potent inhibitor of p38-MAPKα and p38-MAPKβ2 [42] ) had no effect on ET-1-or PMA-stimulated expression of c-jun mRNA (Figure 2 ), indicating that these p38-MAPKs are not involved in this response. Perhaps more surprisingly, SP600125, which inhibits JNKs [32] and suppressed phosphorylation of c-Jun in myocytes exposed to ET-1 or subjected to hyperosmotic shock ( Figure 6D ), had no effect on the up-regulation of c-jun mRNA in myocytes exposed to ET-1 (Figure 3 ). These data strongly indicate that c-Jun does not operate in a positive feedback system to promote its own upregulation and that, of the MAPKs, ERK1\2 is the principal signalling pathway which regulates c-jun expression in myocytes following hypertrophic stimulation. The transcription factor binding sites in the c-jun promoter which are important in upregulation of the mRNA by ET-1 are not entirely clear and await further investigation.
As with c-jun mRNA, up-regulation of c-Jun protein by ET-1 in cardiac myocytes was suppressed by inhibitors of PKC and the ERK cascade ( Figures 6A and 6B) . This is consistent with other studies which show that PD98059 inhibits up-regulation of c-Jun protein in Ras-transformed NIH-3T3 cells [43] , and also inhibits up-regulation of c-Jun protein in response to lysophosphatidic acid in Rat-1 cells [44] . From our data it is clear that a principal effect of ERKs is exerted at the level of c-jun transcription (Figure 2 ), which obviously affects the expression of c-Jun protein. However, the level of c-jun mRNA is not the only important factor in up-regulation of the protein. Although both ET-1 and PMA induced comparable increases in the expression of c-jun mRNA ( Figures 1A and 1B) , the increase in c-Jun protein in myocytes exposed to PMA was significantly less than that induced by ET-1 ( Figure 5D ). This suggests that c-Jun protein levels are also regulated post-transcriptionally, either by increased translation or decreased degradation. It is well-established that PMA, ET-1 and α " -adrenergic agonists increase overall translation rates in cardiac myocytes [45] [46] [47] , and the PI3K\protein kinase B pathway may play a role in stimulating translational activity [48] . However, inhibition of this pathway with LY294002 had no effect on ET-1-induced up-regulation of c-Jun protein ( Figures 6A and 6B) . While it is possible that other pathways may regulate the rate of c-Jun synthesis, our data are more consistent with the alternative possibility, that ET-1 increases c-Jun protein stability and this effect is mediated through JNKs (Figure 7) . Inhibition of JNKs with SP600125 increased the rate of decline of c-Jun protein following exposure to ET-1. This suggests that JNKs do play a significant role in cJun up-regulation, albeit at a post-transcriptional level, rather than through increasing c-jun mRNA. Cycloheximide inhibits protein synthesis, but potently activates JNKs [35] and, consistent with a role for JNKs in increasing c-Jun stability, there was no decline in c-Jun levels in myocytes exposed to cycloheximide alone following ET-1 stimulation. The role of JNKs in promoting c-Jun stability (rather than other stress-responsive pathways) was confirmed using SP600125, which increased the rate of degradation of c-Jun in the presence of cycloheximide. These data are consistent with studies in other cells which indicate that phosphorylation of c-Jun(Ser-73) by JNKs, in addition to increasing c-Jun transactivating activity, appears to increase cJun protein stability by reducing ubiquitination [49] [50] [51] . However, confusingly, some studies have suggested that JNKs may increase c-Jun ubiquitination under some circumstances [49] . Although Ser-63 and Ser-73 are the key sites which regulated cJun transactivating activity, c-Jun is also phosphorylated by JNKs on Thr-91\Thr-93 [52] . The function of these phosphorylations is unclear but they may result in the dephosphorylation of Ser residues in the C-terminal DNAbinding domain of c-Jun [52] to increase DNA binding [53] . This seems unlikely in cardiac myocytes where hyperosmotic shock powerfully activates the JNKs [29] , but does not increase the binding of c-Jun to the AP-1 sequence (J. G. Harrison and A. Clerk, unpublished work). Alternatively, the phosphorylation of Thr-91\Thr-93 could perhaps contribute to the stabilization of cJun protein.
In conclusion, in cardiac myocytes following hypertrophic stimulation, ERK1\2 are the principal MAPKs which are important in the up-regulation of c-jun mRNA and, conse- This work was supported by the British Heart Foundation, the Medical Research Council and the Wellcome Trust.
